Horizon Europe European Union
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · European Union
Development of predictive biomarkers of disease progression and treatment response by using AI methodologies…
Full title in the source: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Open
The EU's Horizon Europe programme expects to make 6 awards of €6 million – €8 million each, from a total budget of €44.2 million. Applications close on 17 Feb 2027 (EU calls usually close at 17:00 Brussels time). Organisations in EU member states and Horizon Europe associated countries such as Türkiye can usually take part; the topic conditions control.
- Deadline
- 17 Feb 2027 (in 94 days)
- Grant amount
- €6 million – €8 million per project
- Total budget
- €44.2 million
- Funding rate
- 100% of eligible costs Standard rule for this programme; the call can differ.
- Total budget
- €44.2 million
- Expected awards
- 6
- Type of action
- HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
- Likely applicant types
- Companies, SMEs / start-ups, Non-profits, Universities & research, Public bodies From source categories or programme rules; the call decides.
- Funder
- Horizon Europe (HORIZON)
- Reference
- HORIZON-HLTH-2027-02-TOOL-01-two-stage
- Call
- HORIZON-HLTH-2027-02-two-stage
- Last checked
- 14 Nov 2026
Expected outcome
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• Clinical researchers and developers have access to novel predictive biomarkers to guide a more accurate assessment of disease progression and treatment response and tackle the unmet clinical needs of non-communicable chronic diseases.
• Clinicians and healthcare professionals use clinically validated predictive biomarkers for implementing more effective clinical research and personalised medicine with better health outcomes in chronic non-communicable diseases.
• Key stakeholders have access to trustworthy Artificial Intelligence (AI) tools to guide the development of multimodal predictive biomarkers of higher accuracy and clinical value when compared to the established practice.
Read the full text
• The citizens benefit of better health outcomes thanks to improved clinical guidelines and the implementation of effective biomarker-guided clinical research and personalised healthcare.
Scope
Biomarkers [1] are invaluable tools for improving patient outcomes, guiding treatment decisions, accelerating personalised medicine, more effective clinical research and the development of better medicines.
However, despite the scientific discoveries of many clinically relevant biomarkers, estimated on the scale of tens of thousands, only a few biomarkers have been implemented in clinical practice. The traditional ‘one biomarker’ paradigm is insufficient for addressing the unmet clinical needs of chronic, progressive and multifactorial diseases, due to the complexity of the clinical phenotypes characterised by broad inter-and intra-patient heterogeneity. The established biomarkers have limitations in their use as prognostic and predictive indicators, for the assessment of the disease progression and the choices of the optimal therapeutic interventions tailored to the patients’ characteristics.
Read the full text
Therefore, the topic focuses on the clinical development of predictive biomarkers of disease progression and treatment response for chronic non-communicable diseases (excluding cancer) by using established AI methodologies able to combine data of clinically used and candidate biomarkers, with available data from relevant clinical studies, longitudinal and Real-World Data (RWD) [2] . This topic is expected to support collaborative projects paving the way for future innovations in personalised medicine and enabling more timely and effective therapeutic interventions.
The proposals should address all the following research and innovation activities:
• Set-up a multidisciplinary collaboration to map and evaluate the available information and data on biomarkers currently used in the clinical setting, candidate biomarkers from past and ongoing clinical studies, which are scientifically proven as clinically relevant to the disease progression and treatment response for the chronic non-communicable diseases under study. This should include stratification by biological sex, and where feasible, integration of gender-related variables and sociodemographic determinants that may modulate disease trajectories or treatment efficacy.
• Adapt and apply of established AI methods rather than developing novel ones from scratch, to deliver novel predictive biomarkers of disease progression and treatment response, by integrating data of currently used and candidate biomarkers, with suitable data from available longitudinal and other relevant clinical studies, including RWD, as necessary. To guarantee a solid and fast optimisation and training of the AI tools, the applicants should provide information in their proposal that the appropriate high-quality clinical data are readily available, and when necessary generate small-scale new data for the AI optimisation needs. The biomarkers under study should be multimodal, covering for instance molecular, cellular, physiological, imaging, behavioural and digital markers, and/or their combinations. The applicants should justify why the…
Who can apply
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Applicant categories are a starting point. The official call decides eligibility.
Topics
Biomarkers Chronic diseases Clinical research Clinical trials Personalised medicine Software validation Artificial intelligence Clinical validation In-silico Non-communicable diseases Predictive Biomarkers clinical research
Timing
Two-stage call. Next deadline 2027-02-17; later stage/cut-off 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
How to apply
- Read the full topic on the Funding & Tenders Portal: expected outcome, scope, type of action and the topic conditions, including any country restrictions.
- Register each participating organisation in the Funding & Tenders Portal to get a PIC.
- Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries (Horizon Europe standard rule; Türkiye is associated). Confirm in the topic conditions.
- Prepare Part A (administrative forms and budget, completed in the portal) and Part B (the technical description on the official template for this type of action).
- Submit in the portal before the cut-off time on the deadline day. Late submissions are not accepted.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where these facts come from
| Fact | Value | How we know | Taken from the source |
|---|---|---|---|
| Deadline | 17 February 2027 “Two-stage call. Next deadline 2027-02-17; later stage/cut-off 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).” | official data field | 15 Nov 2026 |
| Amount per applicant | Unknown — not stated in the source we hold | unknown | — |
| Total budget | €44.2 million | official data field | 15 Nov 2026 |
| Funding rate | 100% of eligible costs | programme standard rule | 15 Nov 2026 |
| Who can apply | Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule). | programme standard rule | 15 Nov 2026 |
| Where to apply | Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route. | read from the official text | 15 Nov 2026 |
Official sources
Facts on this page come from the funder’s official data, taken on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.
More from Horizon Europe
Horizon Europe European Union
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe European Union
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe European Union
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe European Union
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…